Effect of embolisation of meningioma on Ki-67 proliferation index

W Paulus, J Meixensberger, E Hofmann, W Roggendorf

Abstract
The proliferation indices (PIs) were determined in 33 meningiomas using two monoclonal antibodies to the Ki-67 antigen (Ki-67 and MIB1). PIs obtained using Ki-67 on frozen material were intermediate between the lowest and highest MIB1 PIs determined in paraffin wax sections. Preoperative embolisation did not influence Ki67 PI, but four of the 15 embolised tumours showed substantially increased MIB1 PIs around embolisation necroses.

Proliferation can be reliably assessed in routinely processed meningioma tissues using MIB1; and increased perinecrotic PIs may occur in embolised meningiomas without being an indication of malignancy.

(J Clin Pathol 1993;46:876–877)

The monoclonal antibody Ki-67, which reacts selectively with the nuclei of proliferating cells, has been used to assess the proliferation of many tumours, including meningiomas.1 2 Because the epitope is destroyed by routine processing, the application of Ki-67 is restricted to fresh tissues. Recently, the monoclonal antibody MIB1 was developed. This has been raised to the recombinant Ki-67 gene product and shown to work with routinely processed tissues.3 4 To evaluate the usefulness of MIB1, we compared Ki-67 and MIB1 in a series of meningiomas; in addition, we examined the effect of preoperative embolisation on the proliferation rate.

Methods
Fresh frozen and formalin fixed, paraffin wax embedded biopsy specimens from 33 meningiomas were studied. Histological subtypes are shown in fig 1. Not included were malignant meningiomas, (tumours showing necrosis as well as at least two additional histological features of malignancy, such as increased number of mitoses, increased cellular density, differentiation, brain infiltration, and nuclear pleomorphism). Fifteen tumours had been embolised two to 36 days before surgical resection to reduce blood loss and to facilitate surgical removal. Superselective embolisation was performed through meningeal branches, mainly of the external carotid artery. Polyvinyl alcohol particles of 150–250 μm in diameter were used (Contour, Interventional Therapeutics Corporation, San Francisco, California, USA).

Immunohistochemical staining of frozen sections (5 μm) using the Ki-67 antibody (Dianova, Hamburg, Germany; dilution 1 in 30 for 1 hour at room temperature, including negative and positive controls) has been described before.1 Immunostaining of paraffin wax sections (5 μm) on slides coated with 3-aminopropyltriethoxysilane (APES) using MIB1 (Dianova; diluted 1 in 10 for 24 hours at 4°C) was performed according to the method of Cattoretti et al5 and the manufacturer’s protocol. In particular, after being dewaxed sections were cooked four times for 5 minutes each in citrate buffer (pH 6-0) in a microwave oven at 600 Watts. The alkaline phosphatase-antialkaline phosphatase (APAAP) technique with neofuchsin development was used for both antibodies.

The percentage of positive nuclei—the proliferation index (PI)—was determined at a magnification of ×250 (Ki-67) or ×200 (MIB1) using an ocular grid. All nuclei from the frozen section were counted, amounting to 1300—41 000 nuclei (mean 11 425 nuclei) per case. Two areas each comprising the total ocular grid and at least 1000 nuclei were evaluated in the paraffin wax sections. One area exhibited the lowest PI and the other the highest PI (unrelated to embolisation necrosis) of the entire paraffin wax section.

Results
Unequivocal and strong labelling was obtained using both the Ki-67 and the MIB1 antibodies. Weak and questionable positivity was seen in only a few nuclei (less than 10%) of unequivocally positive nuclei, but more often with MIB1 than with Ki-67) and was scored as negative. Scattered mitoses present
Effect of embolisation of meningioma on Ki-67 proliferation index

in a few tumours were always positive. Results using both antibodies are shown in fig 1. In all tumours, the Ki-67 PIs obtained on frozen sections was intermediate between the lowest and the highest MIB1 PIs on paraffin wax sections where larger areas could be examined. The lowest MIB1 PI was 0% except for three cases (0-2%, 0-3%, 0-4%). On the other hand, compared with the Ki-67 PIs, the highest MIB1 PI was more than twice as high in 31 of 33 cases, and more than five times as high in 18 cases.

In 10 of 15 embolised tumours either large necroses or necrotic areas characterised by pyknotic nuclei, eosinophilic cytoplasmats, and microcystic degeneration were observed in the paraffin wax section, but not in the frozen section. PIs were the same in embolised and non-embolised tumours (fig 1). Four of 10 cases with necroses, however, showed strongly and focally increased MIB1 PIs (2-1%, 7-1%, 10-2%, 18-5%) in some perinecrotic areas (fig 2), but not in areas unaffected by embolisation.

Discussion
We found similar PIs in frozen and paraffin wax sections from the same meningiomas using the Ki-67 and MIB1 monoclonal antibodies, respectively. The Ki-67 PIs we obtained in the relatively small frozen sections were intermediate between lowest and highest MIB1 PIs in paraffin wax sections. Our results confirm that proliferation can be reliably assessed in routinely processed tissues using MIB1, provided that sections are adequately pretreated, in particular by microwave cooking in citrate buffer. In addition, MIB1 showed pronounced intratumoral heterogeneity. Compared with previous Ki-67 data in meningiomas, the PIs were relatively low in our series, because we did not evaluate foci of highest density of labelled cells or "representative" areas, but the entire frozen section.

Antibodies to proliferating cell nuclear antigen (PCNA) have also been applied to paraffin wax sections of brain tumours to assess proliferation. PCNA antibodies, however, produce a broad spectrum of staining intensities, including manyequivocally positive nuclei leading to a PI dependent on the sensitivity of the immunohistochemical technique used; MIB1 staining generally shows either negative or clearly positive nuclei. Furthermore, both downregulation of PCNA by dexamethasone and deregulated PCNA expression with high scores unrelated to proliferative activity have been described in meningiomas. Therefore, MIB1 seems to be more suitable than PCNA antibodies for the assessment of proliferation, at least in meningiomas.

The appearance of artificial necrobiotic or necrotic areas due to preoperative arterial embolisation has been described before. These areas could be differentiated from tumour necroses unrelated to embolisation by the presence of several of the following four features: (1) a histological pattern composed of eosinophilic cytoplasm, small nuclei with condensed chromatin and microcystic degeneration; (2) large necroses with indistinct borders; (3) presence of embolisation material in large adjacent blood vessels; and (4) lack of additional histological criteria of malignancy.

While Ki-67 PIs did not differ between embolised and non-embolised tumours, we found substantially increased MIB1 PIs around necroses in four of 15 embolised tumours. The increased perinecrotic proliferation in meningiomas might be related to deliberation of growth factors within or around necroses. Alternatively, tumour cells could be induced to enter the cell cycle by the abnormal metabolism around necroses. In any case necroses and increased perinecrotic PIs, which are usually correlated with meningioma malignancy and recurrence, should be carefully interpreted after embolisation, because they may be artificially induced.

Figure 2 Increased number of positive nuclei around embolisation necrosis (MIB1 immunostaining, paraffin wax section).


Effect of embolisation of meningioma on Ki-67 proliferation index.

W Paulus, J Meixensberger, E Hofmann and W Roggendorf

doi: 10.1136/jcp.46.9.876

Updated information and services can be found at:
http://jcp.bmj.com/content/46/9/876

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/